CORD-19:16a812de72963ceda960a168236e8dbe91832d45 / 48146-48314 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T242","span":{"begin":0,"end":168},"obj":"Sentence"}],"text":"Therefore, increasing the serum concentration of specific anti-CNS monoclonal antibodies may be a novel therapeutic treatment for human neurological injury and disease."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T242","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"TextSentencer_T242","span":{"begin":0,"end":168},"obj":"Sentence"},{"id":"T43074","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, increasing the serum concentration of specific anti-CNS monoclonal antibodies may be a novel therapeutic treatment for human neurological injury and disease."}

{"project":"Epistemic_Statements","denotations":[{"id":"T112","span":{"begin":0,"end":168},"obj":"Epistemic_statement"}],"text":"Therefore, increasing the serum concentration of specific anti-CNS monoclonal antibodies may be a novel therapeutic treatment for human neurological injury and disease."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T172","span":{"begin":149,"end":155},"obj":"Disease"}],"attributes":[{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"Therefore, increasing the serum concentration of specific anti-CNS monoclonal antibodies may be a novel therapeutic treatment for human neurological injury and disease."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T120","span":{"begin":26,"end":31},"obj":"Body_part"},{"id":"T121","span":{"begin":63,"end":66},"obj":"Body_part"}],"attributes":[{"id":"A120","pred":"uberon_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A121","pred":"uberon_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"}],"text":"Therefore, increasing the serum concentration of specific anti-CNS monoclonal antibodies may be a novel therapeutic treatment for human neurological injury and disease."}